<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03125564</url>
  </required_header>
  <id_info>
    <org_study_id>FMT-IBS study</org_study_id>
    <nct_id>NCT03125564</nct_id>
  </id_info>
  <brief_title>FMT for Patients With IBS With Fecal and Mucosal Microbiota Assessment</brief_title>
  <official_title>A Randomised, Placebo-controlled Study on Fecal Microbiota Transplantation for Patients With Irritable Bowel Syndrome With Fecal and Mucosal Microbiota Assessment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Irritable bowel syndrome (IBS) is a common functional bowel disorder of the gastrointestinal&#xD;
      tract affecting up to 20 percent of the adolescent and adult populations. It is characterised&#xD;
      by abdominal pain, irregular bowel habits, altered stool consistencies and bloating, and is&#xD;
      associated with impaired quality of life. IBS can be categorised into diarrhoea predominant&#xD;
      type (IBS-D), constipation predominant type (IBS-C), and mixed type (IBS-M). Fecal microbiota&#xD;
      transplantation (FMT) defined as infusion of feces from healthy donors to affected subjects&#xD;
      has shown impressive results with high cure rates in patients with recurrent clostridium&#xD;
      difficile infections. The investigators propose a randomised, placebo-controlled trial of FMT&#xD;
      in patients with IBS.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Irritable bowel syndrome (IBS) is a common functional bowel disorder of the gastrointestinal&#xD;
      tract affecting up to 20 percent of the adolescent and adult populations. It is characterised&#xD;
      by abdominal pain, irregular bowel habits, altered stool consistencies and bloating, and is&#xD;
      associated with impaired quality of life. IBS can be categorised into diarrhoea predominant&#xD;
      type (IBS-D), constipation predominant type (IBS-C), and mixed type (IBS-M). Until recently,&#xD;
      the development of an effective therapy for this condition has been hampered by a poor&#xD;
      understanding of the etiology of the disease. Traditionally the underlying pathogenesis of&#xD;
      IBS has been centered on the brain-gut axis whereby stress and psychological conditions alter&#xD;
      the perception of IBS symptoms. Emerging evidence however supports the observation that at&#xD;
      least in a subgroup of patients with IBS, peripheral mechanisms within the intestine&#xD;
      including low grade mucosal inflammation, abnormal immune activation and altered visceral&#xD;
      sensitivity may be the main drivers of the manifestations in IBS.&#xD;
&#xD;
      Accumulating data suggest that the intestinal microbiota play an important role in the&#xD;
      pathophysiology of IBS. This is derived from early observation that post-infectious IBS&#xD;
      developed in a subgroup of patients following a bout of gastroenteritis. Several studies have&#xD;
      shown that the fecal microbiota was altered in IBS and IBS symptoms can be improved by&#xD;
      therapeutic interventions that target the microbiota including antibiotics, probiotics and&#xD;
      prebiotics. Rifaximin, an oral, non-systemic broad spectrum antibiotics has also been shown&#xD;
      to provide significant relief in IBS symptoms in a randomized controlled trial.&#xD;
&#xD;
      Fecal microbiota transplantation (FMT) defined as infusion of feces from healthy donors to&#xD;
      affected subjects has shown impressive results with high cure rates in patients with&#xD;
      recurrent clostridium difficile infections.The mechanism of FMT in IBS is not completely&#xD;
      clear.&#xD;
&#xD;
      The investigators propose a randomised, placebo-controlled trial of FMT in patients with IBS.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 12, 2017</start_date>
  <completion_date type="Anticipated">July 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of responder</measure>
    <time_frame>12 weeks</time_frame>
    <description>Record 1) worst abdominal pain and 2)stool consistency everyday</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients who had adequate relief of global IBS symptoms</measure>
    <time_frame>12 weeks</time_frame>
    <description>Adequate relief of global IBS symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the onset and duration of relief of IBS symptoms</measure>
    <time_frame>12 weeks</time_frame>
    <description>The onset and duration of relief of IBS symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients who had improvement on worst abdominal bloating</measure>
    <time_frame>12 weeks</time_frame>
    <description>Proportion of patients who had improvement on worst abdominal bloating between the treatment arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the onset and duration of worst abdominal bloating</measure>
    <time_frame>12 weeks</time_frame>
    <description>The onset and duration of worst abdominal bloating assessed by phone interview and on follow up visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients who had improvement of abdominal discomfort</measure>
    <time_frame>12 weeks</time_frame>
    <description>compare the difference in proportion of patients who had improvement on abdominal discomfort between the treatment arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the onset and duration of abdominal discomfort</measure>
    <time_frame>12 weeks</time_frame>
    <description>The onset and duration of abdominal discomfort will be assessed through patient diary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IBS-d global symptoms score</measure>
    <time_frame>12 weeks</time_frame>
    <description>The proportion of patients who had improvement on IBS-d global symptoms score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <condition>Fecal Microbiota Transplantation</condition>
  <arm_group>
    <arm_group_label>Fecal Microbiota Transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FMT infusion and Fecal and Mucosal Microbiota Assessment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham infusion</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Infusion with sham and Fecal and Mucosal Microbiota Assessment</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Fecal Microbiota Transplantation</intervention_name>
    <description>Fecal microbiota transplantation</description>
    <arm_group_label>Fecal Microbiota Transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sham</intervention_name>
    <description>Infusion of sham</description>
    <arm_group_label>Sham infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Fecal and Mucosal Microbiota Assessment</intervention_name>
    <description>To assess the fecal and mucosal microbiota before and after Fecal Microbiota Transplantation</description>
    <arm_group_label>Fecal Microbiota Transplantation</arm_group_label>
    <arm_group_label>Sham infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients are aged 18 or above&#xD;
&#xD;
          -  Patients have a diagnosis of IBS consistent with the Rome III criteria (13)&#xD;
&#xD;
          -  Patients did not have adequate relief of global IBS symptoms and of IBS-related&#xD;
             bloating at both the time of screening and the time of randomization&#xD;
&#xD;
          -  Patients had undergone clinical investigations with colonoscopy within two years of&#xD;
             recruitment&#xD;
&#xD;
          -  Patients with written informed consent form provided&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients have constipation predominant IBS (according to the definition of Rome III&#xD;
             criteria)&#xD;
&#xD;
          -  Patients have a history of inflammatory bowel disease or gastrointestinal malignancy&#xD;
&#xD;
          -  Patients have previous abdominal surgery (other than cholecystectomy or appendectomy)&#xD;
&#xD;
          -  Patients have human immunodeficiency virus infection&#xD;
&#xD;
          -  Patients have renal disease manifested by 1.5 times the ULN of serum creatinine or&#xD;
             blood urea nitrogen level&#xD;
&#xD;
          -  Patients have hepatic disease manifested by twice the upper limit of normal (ULN) for&#xD;
             any of the following liver function tests: alanine aminotransferase, aspartate&#xD;
             aminotransferase, alkaline phosphatase, or total bilirubin (except in isolated&#xD;
             elevation of unconjugated bilirubin&#xD;
&#xD;
          -  Patients have diabetes mellitus manifested by HbA1C &gt; 6.5%&#xD;
&#xD;
          -  Patients have abnormal thyroid function manifested by values of serum Sensitive&#xD;
             Thyroid Stimulating Hormone and serum free T4 fall outside the reference range which&#xD;
             is not controlled by thyroid medications&#xD;
&#xD;
          -  Patients have a history of psychiatric illness (mania and schizophrenia)&#xD;
&#xD;
          -  Patients have depression defined by having a Patient Health Questionnaire-9 (PHQ-9)&#xD;
             score &gt; 15&#xD;
&#xD;
          -  Patients have anxiety defined by having a Generalized Anxiety Disorder 7 (GAD7) score&#xD;
             &gt; 10&#xD;
&#xD;
          -  Patients have active infection at the time of inclusion&#xD;
&#xD;
          -  Patients have used antibiotic therapy or anti-inflammatory drugs within the past 7&#xD;
             days&#xD;
&#xD;
          -  Patients have any other organic causes that can explain the symptoms of IBS&#xD;
&#xD;
          -  Current pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Siew Ng, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese University of Hong Kong</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amy Li</last_name>
    <phone>+852 26373225</phone>
    <email>amyli@cuhk.edu.hk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Whitney Tang</last_name>
    <phone>+852 35051519</phone>
    <email>whitneytang@cuhk.edu.hk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Chinese University of Hong Kong</name>
      <address>
        <city>Sha Tin</city>
        <zip>000000</zip>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Siew Chien Ng, PhD</last_name>
      <phone>35053996</phone>
      <email>siewchienng@cuhk.edu.hk</email>
    </contact>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <reference>
    <citation>Wilson S, Roberts L, Roalfe A, Bridge P, Singh S. Prevalence of irritable bowel syndrome: a community survey. Br J Gen Pract. 2004 Jul;54(504):495-502.</citation>
    <PMID>15239910</PMID>
  </reference>
  <reference>
    <citation>Talley NJ, Spiller R. Irritable bowel syndrome: a little understood organic bowel disease? Lancet. 2002 Aug 17;360(9332):555-64. Review.</citation>
    <PMID>12241674</PMID>
  </reference>
  <reference>
    <citation>Collins SM. A role for the gut microbiota in IBS. Nat Rev Gastroenterol Hepatol. 2014 Aug;11(8):497-505. doi: 10.1038/nrgastro.2014.40. Epub 2014 Apr 22. Review.</citation>
    <PMID>24751910</PMID>
  </reference>
  <reference>
    <citation>Kassinen A, Krogius-Kurikka L, Mäkivuokko H, Rinttilä T, Paulin L, Corander J, Malinen E, Apajalahti J, Palva A. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology. 2007 Jul;133(1):24-33. Epub 2007 Apr 14.</citation>
    <PMID>17631127</PMID>
  </reference>
  <reference>
    <citation>Ng SC, Lam EF, Lam TT, Chan Y, Law W, Tse PC, Kamm MA, Sung JJ, Chan FK, Wu JC. Effect of probiotic bacteria on the intestinal microbiota in irritable bowel syndrome. J Gastroenterol Hepatol. 2013 Oct;28(10):1624-31. doi: 10.1111/jgh.12306.</citation>
    <PMID>23800182</PMID>
  </reference>
  <reference>
    <citation>Gwee KA, Graham JC, McKendrick MW, Collins SM, Marshall JS, Walters SJ, Read NW. Psychometric scores and persistence of irritable bowel after infectious diarrhoea. Lancet. 1996 Jan 20;347(8995):150-3.</citation>
    <PMID>8544549</PMID>
  </reference>
  <reference>
    <citation>Spiller R, Campbell E. Post-infectious irritable bowel syndrome. Curr Opin Gastroenterol. 2006 Jan;22(1):13-7. Review.</citation>
    <PMID>16319671</PMID>
  </reference>
  <reference>
    <citation>Parkes GC, Sanderson JD, Whelan K. Treating irritable bowel syndrome with probiotics: the evidence. Proc Nutr Soc. 2010 May;69(2):187-94. doi: 10.1017/S002966511000011X. Epub 2010 Mar 18. Review.</citation>
    <PMID>20236566</PMID>
  </reference>
  <reference>
    <citation>Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, Mareya SM, Shaw AL, Bortey E, Forbes WP; TARGET Study Group. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011 Jan 6;364(1):22-32. doi: 10.1056/NEJMoa1004409.</citation>
    <PMID>21208106</PMID>
  </reference>
  <reference>
    <citation>van Nood E, Dijkgraaf MG, Keller JJ. Duodenal infusion of feces for recurrent Clostridium difficile. N Engl J Med. 2013 May 30;368(22):2145. doi: 10.1056/NEJMc1303919.</citation>
    <PMID>23718168</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 7, 2017</study_first_submitted>
  <study_first_submitted_qc>April 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2017</study_first_posted>
  <last_update_submitted>April 22, 2021</last_update_submitted>
  <last_update_submitted_qc>April 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Siew Chien NG</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

